Orthocell (ASX:OCC) received the first orders for its peripheral nerve repair device Remplir in Singapore as it advanced its commercialization activities in the market, according to a Thursday filing with the Australian bourse.
The product is set for launch in the first quarter of 2025 via distributor Device Technologies Asia, which also handles the distribution of Remplir in Australia and New Zealand, the filing said.
The company's shares were up almost 5% in recent Thursday trade.
Price (AUD): $1.05, Change: $+0.05, Percent Change: +4.50%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.